Skip to main content
Premium Trial:

Request an Annual Quote

Bio-Rad Laboratories Sees Q3 Sales Rise 4 Percent

NEW YORK (GenomeWeb News) – Bio-Rad Laboratories reported after the market closed on Tuesday that its third-quarter revenues rose 4 percent driven by strong clinical diagnostics sales.

The firm reported total revenues of $461.1 million for the three-month period ended Sept. 30, compared to revenues of $441.8 million for the third quarter of 2008. On a currency-neutral basis, Bio-Rad's revenue growth for the quarter was 11 percent.

It beat analysts' consensus estimate on both the top and bottom line.

Bio-Rad said that its life science products business generated revenues of $150.4 million, a drop of around 4 percent year over year, or less than 1 percent on a currency-neutral basis. Sales of the firm's clinical diagnostic products were $307.5 million, up around 9 percent compared to the period a year ago.

Bio-Rad said that the year-over-year decline in the life science business was impacted by slowed research markets in the US and in Europe.

"As we had expected, the economy continued to have somewhat of a negative impact on customer spending particularly in our Life Science segment, but we are encouraged by the resiliency we've seen in many of our markets," Bio-Rad President and CEO Norman Schwartz said in a statement.

The firm posted a profit of $38.5 million, or $1.38 per share, up from $27.8 million, or $1.00 per share, for the third quarter of 2008.

The company's R&D costs rose 2 percent over the year before to $39.5 million, compared to $38.8 million, while its SG&A spending ticked up to $153.6 million from $150.5 million.

Bio-Rad finished the quarter with $554.2 million in cash and cash equivalents and $87.9 million in short-term investments.

In early Wednesday trade on the New York Stock Exchange, shares of Bio-Rad were up 4 percent at $94.38.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.